Eli Lilly and Company
LLYHealthcare Drug Manufacturers General
Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.
- Revenue
- +38.6%
- EPS
- +16.3%
- Free cash flow
- +21.8%
- Total debt
- +15.0%
Quarter to September 2026, against a year earlier
Follow LLY
Alert me
Ratios over time Q4 FY25 to Q3 FY26
Returns on capital
ROIC was 26.4% in Q3 FY26, against a low of 26.3% in Q2 FY26. ROE, at 86.0%, is far above it because equity is small against the capital the business uses.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| ROE | 101.2% | 107.5% | 102.3% | 86.0% |
| ROIC | 26.6% | 30.2% | 26.3% | 26.4% |
Debt
Net debt is 4.45× a year’s EBITDA. Debt is 1.17× equity, against 1.62× in Q2 FY26.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Debt / equity | 1.6× | 1.3× | 1.6× | 1.2× |
| Net debt / EBITDA | 4.1× | 3.6× | 4.8× | 4.5× |
Cash cycle, in days
Customers pay in 107 days, inventory is held 469 days and suppliers are paid in 149. Cash is tied up for 426 days between paying for goods and being paid.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Cash cycle | 389 | 387 | 402 | 426 |
| Days to pay suppliers | 178 | 148 | 169 | 149 |
| Days to be paid | 113 | 107 | 108 | 107 |
Per share, from Q4 FY25
Since Q4 FY25, per share: free cash flow has grown 120.5%; revenue has grown 33.5%; book value has grown 52.7%.
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Free cash flow | 1.0× | 1.3× | 2.0× | 2.2× |
| Revenue | 1.0× | 1.1× | 1.2× | 1.3× |
| Book value | 1.0× | 1.2× | 1.3× | 1.5× |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
46.83 | 32.67 | 40.25 | 37.56 |
P/S ratio |
14.79 | 11.39 | 13.44 | 11.94 | |
P/FCF ratio |
86.31 | 58.67 | 52.49 | 47.21 | |
P/Operating CF |
299.01 | 154.27 | 100.13 | 90.55 | |
P/B ratio |
36.34 | 26.37 | 31.59 | 25.63 | |
Price to Tangible BV |
68.31 | 46.50 | 154.68 | 83.81 | |
EV/Sales |
15.34 | 11.88 | 14.01 | 12.50 | |
EV/EBITDA |
35.32 | 25.58 | 31.24 | 29.23 | |
EV/Operating CF |
59.45 | 41.92 | 39.75 | 35.28 | |
EV/FCF |
89.46 | 61.21 | 54.75 | 49.45 | |
Quick Ratio |
0.78 | 0.72 | 0.68 | 0.64 | |
Current Ratio |
1.58 | 1.50 | 1.35 | 1.39 | |
Net Debt/EBITDA |
4.10 | 3.62 | 4.83 | 4.45 | |
Debt/Assets |
37.79% | 33.77% | 38.59% | 31.73% | |
Debt/Equity |
1.60 | 1.26 | 1.62 | 1.17 | |
Asset Turnover |
0.68 | 0.70 | 0.66 | 0.66 | |
Operating CF/Net income |
0.49 | 0.72 | 1.51 | 1.77 | |
Capex/Depreciation |
(4.35) | (4.57) | (5.49) | (5.83) | |
Research and Development Expense of Revenue |
19.70% | 17.73% | 16.62% | 17.41% | |
Selling, General and Administrative Expense of Revenue |
16.24% | 14.82% | 14.93% | 12.81% | |
Intangible Assets out of Total Assets |
0.11 | 0.12 | 0.19 | 0.19 | |
Share Based Compensation of Revenue |
0.70% | 0.81% | 0.87% | 0.82% | |
Graham Net Nets |
(0.03) | (0.04) | (0.04) | (0.04) | |
Graham Number |
123.57 | 148.63 | 159.55 | 176.92 | |
Earnings Yield |
2.14% | 3.06% | 2.48% | 2.66% | |
Free Cash Flow Yield |
1.16% | 1.70% | 1.91% | 2.12% | |
Revenue per Share |
21.50 | 22.13 | 25.74 | 27.35 | |
Operating CF per Share |
3.59 | 5.96 | 11.98 | 12.78 | |
Capex per Share |
(2.84) | (2.60) | (3.29) | (3.56) | |
Free Cash Flow per Share |
0.76 | 3.36 | 8.69 | 9.22 | |
Cash per Share |
8.10 | 5.91 | 10.03 | 5.48 | |
Shareholders Equity per Share |
29.57 | 34.88 | 37.96 | 45.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
29.57 | 34.88 | 37.96 | 45.15 | |
Free Cash Flow |
678.00 | 3,007.00 | 7,757.00 | 8,219.00 | |
Working Capital |
20,401.00 | 18,201.00 | 16,931.00 | 18,267.00 | |
Capital Expenditures |
(2,547.00) | (2,326.00) | (2,933.00) | (3,178.00) | |
Net Current Asset Value |
(30,312.00) | (30,543.00) | (43,732.00) | (42,538.00) | |
EV/EBIT |
38.00 | 27.23 | 33.19 | 31.06 | |
Capex to Sales |
0.13 | 0.12 | 0.13 | 0.13 | |
Price to Operating Income |
36.66 | 26.10 | 31.83 | 29.64 | |
| Other line items | |||||
Average Receivables |
16,715.50 | 17,590.10 | 20,340.30 | 22,344.10 | |
Average Payables |
4,304.00 | 4,235.50 | 5,093.85 | 5,027.60 | |
Average Inventory |
10,666.50 | 11,920.00 | 13,903.40 | 15,187.20 | |
Average Assets |
95,595.50 | 102,982.40 | 121,602.80 | 131,503.70 | |
Average Common Equity |
20,403.50 | 23,522.40 | 26,114.05 | 32,060.90 |